Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments

Table 9 A partial list of ongoing clinical trials

Phase	Trial identifier	Design	Drugs	Enrollment	Expected end date
I	NCT01872065	Double-blind, randomized	ARC520	44	October 2013
	NCT01590641	Double-blind, randomized	GS-9620	48	September 2013
II	NCT00524173	Open-label, randomized	TDF vs TDF + emtricitabine	100	January 2015
	NCT01204762	Double-blind, randomized	IFN-λ + ETV	170	July 2017
	NCT01242787	Open-label, randomized	LB80380	115	September 2012
III	NCT01595685	Open-label, randomized	TBV vs ETV	184	December 2014
	NCT01369199	Open-label, randomized	8 wk ETV followed by 40 wkPEG-IFN-α-2a + ETV	250	May 2016
IV	NCT01804387	Open-label, randomized	TBV + ADV vs LAM + ADV	60	May 2014
	NCT01906580	Open-label, randomized	PEG-IFN-α-2a vs ETV	105	July 2014

Full details of the clinical trials may be found on the United States National Institutes of Health. Available from: URL: http://www.clinicaltrials.gov. LAM: Lamivudine; ETV: Entecavir; ADV: Adefovir; TBV: Telbivudine; TDF: Tenofovir disoproxil fumarate; PEG-IFN: Pegylated interferon.